<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Histopathologic grading of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (BE) shows substantial interobserver and intraobserver variation </plain></SENT>
<SENT sid="1" pm="."><plain>We used immunohistochemical analysis with a set of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell markers, ie, epidermal growth factor receptor (EGFR), ERBB2 (HER2/neu), MYC, CDKN2A (p16), SMAD4, MET, CCND1 (cyclin D1), CTNNB1 (beta-catenin), and TP53 (p53), in histologic sections of endoscopic biopsies of 86 patients with BE in various stages of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The markers, except SMAD4, were scored as 0 (&lt;1% of cells stained), 1 (1%-25%), 2 (26%-50%), or 3 (&gt;50%) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> markers, except EGFR, showed a significant trend for immunohistochemical protein overexpression during malignant progression in BE (P &lt;.01) </plain></SENT>
<SENT sid="4" pm="."><plain>When the successive stages along the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (LGD)-high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD)-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> axis were compared, protein overexpression of beta-catenin separated LGD from <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, whereas protein overexpression of cyclin D1 and p53 discriminated HGD from LGD (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt;.001) </plain></SENT>
<SENT sid="5" pm="."><plain>beta-Catenin can be helpful for a diagnosis of LGD in BE, although it stains positively in a subset only, whereas p53 remains an appropriate marker to define HGD </plain></SENT>
<SENT sid="6" pm="."><plain>In case of doubt, cyclin D1 can be added to separate LGD from HGD in BE </plain></SENT>
</text></document>